Viewing data from:

CEFOXITIN

ANDA

CEFOXITIN SODIUM | A065011 | FRESENIUS KABI USA LLC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Cefoxitin (2023)

Total Spending

$386K

Total Claims

1,506

Beneficiaries

390

Avg Cost/Unit

$8.36

Spending Trend

$336K(2019)→$524K(2020)→$486K(2021)→$397K(2022)→$386K(2023)

YoY Change:-53.2%

5yr CAGR:+11.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs4 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

ACS DOBFAR SPACEFOXITIN SODIUM (STERILE BULK)

DMF 129761998

ORCHID PHARMA LTDCEFOXITIN SODIUM USP (STERILE)

DMF 181492005

ANTIBIOTICOS DO BRASIL LTDAInactiveCEFOXITIN SODIUM STERILE BULK

DMF 197892006

ACS DOBFAR SPAInactiveCEFOXITIN SODIUM USP STERILE 100 GRAMS

DMF 206352007

FRESENIUS KABI ANTI INFECTIVES SRLInactiveCEFOXITIN SODIUM (STERILE) DRUG SUBSTANCE

DMF 206982007

AUROBINDO PHARMA LTDInactiveCEFOXITIN SODIUM USP (STERILE BULK)

DMF 213292008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 3, 2000	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 10GM BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jul 3, 2000

No patent or exclusivity listings for this strength.